2月19日 - ** 制药商 Supernus Pharmaceuticals SUPN.O股价盘前下跌约 22% 至 31 美元
** 周二晚些时候，该公司称 (link) 其抑郁症药物 SPN-820 在一项中期试验中没有达到减轻抑郁症状的主要目标
** 试验测试了250名耐药性抑郁症患者，结果发现与安慰剂相比，SPN-820在统计学上没有明显变化。
** 试验使用蒙哥马利-阿斯伯格抑郁评分量表来测量抑郁症状的严重程度，如悲伤、内心紧张、睡眠减少和感觉不到
** 2024 年，SUPN 的收益率为 30.4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.